Stay updated with breaking news from B Cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A team of international scientists has recently revealed that T cell responses induced by coronavirus disease 2019 (COVID-19) vaccines are able to cross-recognize different variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The study is currently available on the bioRxiv* preprint server.
A new study found increases in resting memory B cell subsets showed strong cross-reactivity against several variants, including Omicron.
Scientists at the La Jolla Institute for Immunology have uncovered how loss of TET enzymes can lead to B cell lymphoma. Their research, published in Nature Immunology, could potentially open opportunities for designing drug treatment strategies to target malignant cells in many cancers.
Infection-fighting B cells retain better memory of the coronavirus spike protein in University Hospital patients who recover from less-severe cases of COVID-19 than in those recovering from severe COVID-19, a new study suggests.
In a new study, published on the bioRxiv* preprint server, scientists showed in a mice model that three doses of the same synthetic peptide vaccine, eliciting an exclusive CD8+ T cell response against one SARS-CoV-2 Spike epitope, protected against lethal SARS-CoV-2 infection, in the absence of neutralizing antibodies. Researchers also showed that the third dose resulted in superior generation of effector-memory T cells in the circulation and tissue-resident memory T (TRM) cells.